Zoetis Inc. $ZTS Shares Purchased by Swedbank AB

Key Points

• Swedbank AB increased its stake in Zoetis Inc. by 3.2%, now holding approximately 1,975,683 shares valued at around $325 million.
• Zoetis reported a quarterly earnings of $1.76 EPS, exceeding estimates and indicating a 4.2% revenue increase year-over-year.
• A range of institutional investors have made significant changes to their holdings, with over 92.80% of Zoetis's stock now owned by institutional investors.

Swedbank AB grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,975,683 shares of the company's stock after buying an additional 60,433 shares during the quarter. Swedbank AB owned 0.44% of Zoetis worth $325,296,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ZTS. Nuveen LLC acquired a new position in Zoetis in the first quarter valued at approximately $616,375,000. Sarasin & Partners LLP acquired a new position in shares of Zoetis in the 1st quarter valued at $339,111,000. Mackenzie Financial Corp boosted its holdings in Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after buying an additional 1,782,110 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after buying an additional 1,747,423 shares in the last quarter. Finally, Polen Capital Management LLC increased its holdings in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

ZTS traded down $2.28 during trading on Friday, reaching $148.33. The company's stock had a trading volume of 3,111,229 shares, compared to its average volume of 2,249,190. The company has a market cap of $65.74 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 2.38 and a beta of 0.88. The firm has a fifty day simple moving average of $152.32 and a two-hundred day simple moving average of $157.21. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the business earned $1.56 earnings per share. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Argus restated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.